Beam cuts 20% of staff, looks to partner on base-edited CAR-T one month after dosing first patient
Beam Therapeutics is slimming down its pipeline of base editing programs and laying off around 100 employees, the company disclosed Thursday.
The biotech said it will now focus on four key programs — its ex vivo sickle cell therapy (known as BEAM-101), an in vivo sickle cell treatment, an alpha-1 antitrypsin deficiency (AATD) therapy and ESCAPE, its program that aims to reduce the toxicity from the conditioning regimen used in bone marrow transplants.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
